全文获取类型
收费全文 | 178974篇 |
免费 | 11470篇 |
国内免费 | 706篇 |
专业分类
耳鼻咽喉 | 2503篇 |
儿科学 | 4876篇 |
妇产科学 | 3435篇 |
基础医学 | 23193篇 |
口腔科学 | 3546篇 |
临床医学 | 17504篇 |
内科学 | 38305篇 |
皮肤病学 | 2801篇 |
神经病学 | 17951篇 |
特种医学 | 6215篇 |
外国民族医学 | 13篇 |
外科学 | 26475篇 |
综合类 | 2302篇 |
现状与发展 | 3篇 |
一般理论 | 201篇 |
预防医学 | 13297篇 |
眼科学 | 4863篇 |
药学 | 11515篇 |
中国医学 | 203篇 |
肿瘤学 | 11949篇 |
出版年
2023年 | 697篇 |
2022年 | 1219篇 |
2021年 | 2862篇 |
2020年 | 1762篇 |
2019年 | 2888篇 |
2018年 | 3400篇 |
2017年 | 2455篇 |
2016年 | 2862篇 |
2015年 | 3456篇 |
2014年 | 5112篇 |
2013年 | 7883篇 |
2012年 | 11397篇 |
2011年 | 12253篇 |
2010年 | 6840篇 |
2009年 | 6308篇 |
2008年 | 11539篇 |
2007年 | 12313篇 |
2006年 | 11809篇 |
2005年 | 12172篇 |
2004年 | 11556篇 |
2003年 | 11033篇 |
2002年 | 10639篇 |
2001年 | 1488篇 |
2000年 | 1135篇 |
1999年 | 1594篇 |
1998年 | 2330篇 |
1997年 | 2020篇 |
1996年 | 1703篇 |
1995年 | 1582篇 |
1994年 | 1425篇 |
1993年 | 1352篇 |
1992年 | 1049篇 |
1991年 | 952篇 |
1990年 | 834篇 |
1989年 | 820篇 |
1988年 | 839篇 |
1987年 | 723篇 |
1986年 | 842篇 |
1985年 | 916篇 |
1984年 | 1221篇 |
1983年 | 1176篇 |
1982年 | 1639篇 |
1981年 | 1512篇 |
1980年 | 1416篇 |
1979年 | 785篇 |
1978年 | 906篇 |
1977年 | 800篇 |
1976年 | 707篇 |
1975年 | 566篇 |
1974年 | 593篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
103.
104.
105.
106.
Trawat Attarbaschi Julia Sacher Thomas Geiss-Granadia Nikolas Klein Nilufar Mossaheb Rupert Lanzenberger Susanne Asenbaum Robert Dudczak Siegfried Kasper Johannes Tauscher 《European neuropsychopharmacology》2007,17(2):102-107
We explored the relationship between striatal dopamine-2 (D(2)) receptor occupancy and extra-pyramidal symptoms (EPS) in bipolar patients receiving olanzapine. Seventeen patients with a DSM-IV diagnosis of bipolar disorder were treated with 5-45 mg/day olanzapine for at least 14 days. After that period, D(2) receptor occupancy was determined using Iodobenzamide (IBZM) and SPECT. EPS were assessed by the Simpson-Angus Scale (SAS) and Barnes-Akathisia Scale (BAS). We found a dose-dependent increase in occupancy: 5 mg led to 28-50%, 10 mg to 40-68%, 15 mg to 69%, 20 mg to 57-66%, 30 mg to 66% and 45 mg to 80% D(2) receptor occupancy; and a significant correlation between plasma levels and occupancy (R(2)=.55, P=.001). Similar to schizophrenic patients, bipolar patients did not exhibit EPS at D(2) occupancy levels of 28 to 80%. Although we did not find an increased vulnerability for acute EPS in bipolar patients receiving olanzapine at clinical relevant doses, this needs to be replicated with larger sample sizes. 相似文献
107.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
108.
Regula E Egli Thomas L Kash Kevin Choo Valentina Savchenko Robert T Matthews Randy D Blakely Danny G Winder 《Neuropsychopharmacology》2005,30(4):657-668
The bed nucleus of the stria terminalis (BNST) and its adrenergic input are key components in stress-induced reinstatement and maintenance of drug use. Intra-BNST injections of either beta-adrenergic receptor (beta-AR) antagonists or alpha2-adrenergic receptor (alpha2-AR) agonists can inhibit footshock-induced reinstatement and maintenance of cocaine- and morphine-seeking. Using electrophysiological recording methods in an in vitro slice preparation from C57/Bl6j adult male mouse BNST, we have examined the effects of adrenergic receptor activation on excitatory synaptic transmission in the lateral dorsal supracommissural BNST (dBNST) and subcommissural BNST (vBNST). Alpha2-AR activation via UK-14,304 (10 microM) results in a decrease in excitatory transmission in both dBNST and vBNST, an effect predominantly dependent upon the alpha2A-AR subtype. Beta-AR activation via isoproterenol (1 microM) results in an increase in excitatory transmission in dBNST, but not in vBNST. Consistent with the work with receptor subtype specific agonists, application of the endogenous ligand norepinephrine (NE, 100 microM) elicits two distinct effects on glutamatergic transmission. In dBNST, NE elicits an increase in transmission (62% of dBNST NE experiments) or a decrease in transmission (38% of dBNST NE experiments). In vBNST, NE elicits a decrease in transmission in 100% of the experiments. In dBNST, the NE-induced increase in synaptic transmission is blocked by beta1/beta2- and beta2-, but not beta1-specific antagonists. In addition, this increase is also reduced by the alpha2-AR antagonist yohimbine and is absent in the alpha2A-AR knockout mouse. In vBNST, the NE-induced decrease in synaptic transmission is markedly reduced in the alpha2A-AR knockout mouse. Further experiments demonstrate that the actions of NE on glutamatergic transmission can be correlated with beta-AR function. 相似文献
109.
Leslee J. Shaw Romalisa Miranda-Peats Piotr Slomka John Friedman Sean W. Hayes Daniel S. Berman Gary V. Heller Marcin Dada William E. Boden Paul Casperson Robert A. O’Rourke Ronald Schwartz William S. Weintraub David J. Maron Spencer King Koon Teo Pamela Hartigan 《Journal of nuclear cardiology》2006,13(5):685-698
Background Stress gated myocardial perfusion single photon emission computed tomography (gSPECT) is increasingly used before and after
intercurrent therapeutic intervention and is the basis for ongoing evaluation in the Department of Veterans Affairs clinical
outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial.
Methods and Results The COURAGE trial is a North American multicenter randomized clinical trial that enrolled 2287 patients to aggressive medical
therapy vs percutaneous coronary intervention plus aggressive medical therapy. Three COURAGE nuclear substudies have been
designed. The goals of substudy 0 are to examine the diagnostic accuracy of the extent and severity of inducible ischemia
at baseline in COURAGE patients compared with patient symptoms and quantitative coronary angiography and to explore the relationship
between inducible ischemia and the benefit from revascularization when added to medical therapy. Substudy 1 will correlate
the extent and severity of provocative ischemia with the frequency, quality, and instability of recurrent symptoms in postcatheterization
patients. Substudy 2 (n _ 300) will examine the usefulness of sequential gSPECT monitoring 6 to 18 months after therapeutic
intervention. Together, these nuclear substudies will evaluate the role of gSPECT to determine the effectiveness of aggressive
risk-factor modifications, lifestyle interventions, and anti-ischemic medical therapies with or without revascularization
in reducing patients’ ischemic burdens.
Conclusions The unfolding of evidence on the application of gSPECT in trials such as COURAGE defines a new era for nuclear cardiology.
We hope the evidence that emerges from the COURAGE trial will further establish the role of nuclear imaging in the evidence-based
management of patients with stable coronary disease.
The COURAGE trial was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research
and Development in collaboration with the Canadian Institutes of Health Research. Unrestricted research grants were obtained
from Merck & Co; Pfizer Pharmaceuticals; Bristol-Myers Squibb Medical Imaging; Astellas Pharma; Kos Pharmaceuticals; Data
Scope; Astra Zeneca Pharmaceuticals; Astra-Zeneca-Canada; Schering-Plough Coorporation, Ltd; Sanofi-Aventis, Inc; First Horizon;
and GE Healthcare. All industrial funding for this trial was directed through the Department of Veterans Affairs. Additional
funding for this substudy was provided by grants to the Department of Veterans Affairs and Canadian Institutes of Health Research
from Astellas Pharma and Bristol-Myers-Squibb Medical Imaging. 相似文献
110.
Robert J Barry 《International journal of psychophysiology》2006,62(3):353-366
We commonly teach beginning science students that theory generates hypotheses which direct our research, framing our experimental observations; and that in turn, these supply the data which support or contradict theory, allowing its self-correction and further development. These propositions are explored here in the context of psychophysiology, concentrating on examples in relation to the Orienting Reflex (OR). It is demonstrated that the realist approach generally portrayed in our teaching about theory and theory testing is not the dominant ethos in this field. Indeed, we pay little more than lip-service to the ideal we teach about. One outcome described here is that the promise offered us by the OR in the 1960s has not been realised. It is argued that this failure may be symptomatic of much of science, suggesting that we need to consciously work to raise the perceived value of theory. The ideation element of theoretical activity can be fostered, and it is argued that we need to do so explicitly at a number of levels in the education of our students, beginning in the early coursework stages and continuing in their research training and development. 相似文献